News
ATHA
2.065
+1.23%
0.025
Weekly Report: what happened at ATHA last week (0415-0419)?
Weekly Report · 2d ago
Athira Pharma (ATHA) Price Target Increased by 7.49% to 7.57
NASDAQ · 04/17 05:19
Athira Pharma's US$14m Market Cap Fall Books Insider Losses
Athira Pharma, Inc. Insiders bought US$243.0k worth of shares in the last year. The average price of the stock is US$3.04. The biggest insider purchase was by Andrew Gengos for US$192k. Athira Pharma owns 7.4% of the company. The company has seen a 15% decline in its share price in the past year. It's important to keep in mind the insider transactions of a company. In the last 12 months Athira pharmy insiders bought 80.01k shares at an average of US$2.06.
Simply Wall St · 04/16 12:46
Athira Pharma Appoints Javier San Martin As New Chief Medical Officer
NASDAQ · 04/15 11:35
*Athira Pharma Appoints Javier San Martin Chief Medical Officer >ATHA
Dow Jones · 04/15 11:02
ATHIRA PHARMA APPOINTS JAVIER SAN MARTIN, M.D., AS CHIEF MEDICAL OFFICER
Reuters · 04/15 11:00
Press Release: Athira Pharma Appoints Javier San -2-
Actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements. You should not place undue reliance on the forward- looking statements. The company's shares are trading at a low of $16.50.     
Dow Jones · 04/15 11:00
Press Release: Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer. Dr. San Martin brings more than 25 years of drug development experience to the company. He is an experienced clinical development leader with a strong track record of advancing drugs from early development to approval and commercialization. Athira is a late-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration.
Dow Jones · 04/15 11:00
Weekly Report: what happened at ATHA last week (0408-0412)?
Weekly Report · 04/15 09:27
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease
Fosgonimeton treatment improved cognitive performance in an Aβ rat model of Alzheimer's disease. In primary rat cortical neurons challenged with Aβ, treatment improved neuronal survival and reduced tau hyperphosphorylation following Aβ injury. The drug also reduced mitochondrial stress and apoptotic signaling.
Benzinga · 04/11 11:09
Weekly Report: what happened at ATHA last week (0401-0405)?
Weekly Report · 04/08 09:28
Weekly Report: what happened at ATHA last week (0325-0329)?
Weekly Report · 04/01 09:28
Is Stryker (SYK) Stock Outpacing Its Medical Peers This Year?
NASDAQ · 03/29 13:40
ANGI, MLKN and KOD are among after hour movers
On the Move ANGI, MLKN and KOD are among after hour movers. ATHA, XERS, KOD, PHAT, INZY, NAMSW, LENZ are among the day's losers. MillerKnoll is down 13%.
Seeking Alpha · 03/27 20:50
12 Health Care Stocks Moving In Wednesday's After-Market Session
Avalo Therapeutics (NASDAQ:AVTX) shares moved upwards by 215.8% to $15.0 during Wednesday's after-market session. The company's Q4 earnings report came out today. Fresh2 Group stock rose upwards by 5.26% as well.
Benzinga · 03/27 20:31
Weekly Report: what happened at ATHA last week (0318-0322)?
Weekly Report · 03/25 09:29
Weekly Report: what happened at ATHA last week (0311-0315)?
Weekly Report · 03/18 09:28
Weekly Report: what happened at ATHA last week (0304-0308)?
Weekly Report · 03/11 09:28
Athira Pharma Shares Slide
NASDAQ · 03/08 15:03
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD 2024 International Conference
Athira Pharma is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. The company presented new clinical and preclinical data on fosgonimeton at the AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's.
Benzinga · 03/08 12:01
More
Webull provides a variety of real-time ATHA stock news. You can receive the latest news about Athira Pharma, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ATHA
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline consists of both blood brain barrier permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system, and other indications. Its lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, small molecule positive modulator of the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) system for CNS disorders. It is also evaluating other drug candidates for the potential treatment of neuropathic pain, amyotrophic lateral sclerosis, Parkinson's disease, and other neurodegenerative diseases. Its ATH-1020 has completed a Phase I single ascending dose evaluation in healthy volunteers. Its ATH-1105 is a small molecule compound designed to be an orally available, once-daily treatment to enhance the HGF/MET system.